Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (SIGHT) 2
Launched by UNIVERSITY OF MICHIGAN · Apr 11, 2025
Trial Information
Current as of August 21, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (SIGHT) 2 trial is designed to compare two different ways of checking for serious eye diseases that can lead to blindness, such as glaucoma, diabetic retinopathy, and cataracts. This study will look at how well a new technology-based approach works compared to the standard eye exam usually done by eye doctors.
To participate, you should be between 65 and 74 years old and speak either English or Spanish. Unfortunately, if you have severe eye pain, a sudden change in your vision, double vision, certain cognitive issues, are pregnant, or have previously turned down participation in a study, you won’t be eligible. If you do join, you can expect to receive eye exams that might help catch these eye diseases early, which is important for maintaining good vision. Keep in mind that the trial is not yet recruiting participants, so it may take some time before you can get involved.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Speak English or Spanish
- Exclusion Criteria:
- • 1) significant eye pain (2) sudden decrease in vision within one week (3) binocular diplopia (4) cognitive impairment (5) pregnancy, or (6) previously declined participation
About University Of Michigan
The University of Michigan, a leading academic institution renowned for its commitment to advancing healthcare and medical research, serves as a prominent clinical trial sponsor. With a robust infrastructure that supports innovative research initiatives, the university leverages its multidisciplinary expertise to conduct a wide array of clinical trials aimed at improving patient outcomes and advancing medical knowledge. Through its state-of-the-art facilities and collaborative environment, the University of Michigan fosters partnerships between researchers, clinicians, and industry leaders, ensuring the development of cutting-edge therapies and interventions that address pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Flint, Michigan, United States
Patients applied
Trial Officials
Paula Anne Newman-Casey, MD
Principal Investigator
University of Michigan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported